ProfileGDS5678 / 1424544_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 22% 21% 22% 23% 23% 20% 22% 43% 45% 23% 22% 22% 22% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.536222
GSM967853U87-EV human glioblastoma xenograft - Control 22.5020521
GSM967854U87-EV human glioblastoma xenograft - Control 32.527222
GSM967855U87-EV human glioblastoma xenograft - Control 42.4930623
GSM967856U87-EV human glioblastoma xenograft - Control 52.4848123
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.54220
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.555422
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9772743
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0224445
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5219623
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5074222
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4863322
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5151422
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4999721